Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cystic fibrosis drug boost brain blood flow in heart failure?

NCT ID NCT07695090

Recruiting now Disease control Sponsor: Qanatpharma AG Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether lumacaftor, a drug used for cystic fibrosis, can improve blood flow to the brain and thinking abilities in people with stable heart failure and reduced pumping function. About 60 participants will receive either lumacaftor or a placebo for one month. The goal is to see if restoring a specific protein function can help protect the brain in heart failure patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lumacaftor
What this could lead to
If it works, this could point toward a treatment for cognitive decline in heart failure patients, addressing a currently unmet need.
What could go wrong
This is a small, early-phase proof-of-concept study. It may not show benefit, and side effects are possible. Success in this trial does not guarantee a future approved therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Michael's Hospital

    RECRUITING

    Toronto, Ontario, M5B 1M8, Canada

    Contact

    Contact

  • University Health Network (UHN) Peter Munk Cardiac Centre

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G2N2, Canada

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.